The rationale behind the study rests on a strategy that has gained considerable traction in oncology: drug repurposing. Bringing a brand-new molecule from discovery to the clinic can take well over a decade and cost more than a billion dollars, whereas established drugs come with known safety profiles, manufacturing routes, and, in some cases, prior human exposure data. Clofoctol, an antibiotic with a long clinical history in parts of Europe, had already attracted attention for direct antitumor activity in preclinical studies. What remained poorly understood—and what motivated the Beijing team led by Yue Wang, Wei Han, and Xiaozhong Peng—was whether the drug could also act on the immune landscape of glioblastoma, a tumor whose microenvironment is famously hostile to infiltrating lymphocytes.

To probe that question, the researchers turned to an orthotopic GL261 model, in which glioblastoma cells are implanted directly into the brains of immunocompetent mice. This model is widely regarded as one of the most faithful experimental systems for glioblastoma immunology because it preserves an intact blood-brain barrier and an intact immune system, both of which are essential when the question at hand concerns systemic immune trafficking. Using flow cytometry, the team compared the immune composition of tumors from clofoctol-treated animals against controls, and the differences were striking. Tumors from treated mice contained a substantially higher proportion of CD8-positive cytotoxic T cells—the immune system’s primary tumor-killing operatives—and those cells expressed elevated levels of cytotoxic effector molecules, hallmarks of a tumor microenvironment shifting from immunologically cold to immunologically active.

Perhaps the most intriguing finding, however, lay outside the tumor itself. When the researchers analyzed the composition of cells in the bone marrow, they observed that glioblastoma was associated with an accumulation of T cells sequestered in that compartment, a phenomenon consistent with the systemic T-cell dysfunction that increasingly is recognized as a barrier to immunotherapy in brain tumors. Clofoctol treatment partially relieved this sequestration, promoting a redistribution of T cells back into systemic circulation and, ultimately, into the tumor. In other words, the drug appears to work not only within the tumor microenvironment but at the level of whole-body immune architecture, releasing a reservoir of cytotoxic lymphocytes that the tumor had effectively locked away.

The causal importance of CD8-positive T cells to the therapeutic effect was confirmed in a depletion experiment. When the researchers eliminated CD8-positive T cells from the animals, the antitumor efficacy of clofoctol was markedly attenuated. That result matters because it elevates the drug from a possible bystander to a demonstrably T-cell-dependent intervention: whatever else clofoctol may be doing to tumor cells directly, its benefit in this model hinges on the presence of a functional cytotoxic T-cell population. For a field in which many repurposed drugs show antitumor effects that turn out to be independent of immunity—and therefore unlikely to synergize with checkpoint blockade—this distinction is critical.

In vitro co-culture experiments added a second layer of mechanistic support. When CD8-positive T cells were pretreated with clofoctol and then exposed to target cells, their cytotoxic activity increased, accompanied by upregulated expression of granzyme B, perforin, and interferon-gamma—the molecular arsenal that cytotoxic lymphocytes use to punch holes in target-cell membranes and trigger programmed cell death, along with the inflammatory cytokine that amplifies antitumor immune signaling. The drug, in short, did not merely deliver more T cells to the tumor; it made the T cells that arrived more lethal.

To trace the signaling pathway behind this activation, the team employed an affinity-based chemoproteomic approach known as ITSA-MS, which screens for proteins that bind a drug of interest in cellular lysates. That screen identified BCL9, a scaffolding protein best known for its role in Wnt signaling and previously implicated in various cancers, as a candidate clofoctol-responsive protein. Subsequent western blot analyses revealed that clofoctol treatment was associated with increased phosphorylation of VAV1, AKT, and ERK—a cascade of signaling events well established in T-cell activation, in which VAV1 relays receptor proximal signals downstream to AKT and ERK pathways that drive proliferation, survival, and effector differentiation. The authors are careful to note that the precise regulatory relationship between BCL9 and this phosphorylation cascade remains to be worked out, but the convergence of chemoproteomic and biochemical evidence points to a coherent mechanism by which the antibiotic potentiates T-cell function.

The translational payoff came in the combination experiments. Glioblastoma’s failure to respond to PD-1 blockade is thought to stem from multiple converging deficits: a physically and immunologically protected location behind the blood-brain barrier, a profoundly immunosuppressive microenvironment, and a systemic T-cell compartment that is itself dysfunctional. Checkpoint inhibitors address only one link in that chain—releasing the molecular brakes on T cells—but they cannot help if there are too few functional T cells reaching the tumor in the first place. Clofoctol, according to the new data, addresses complementary links in the chain by mobilizing T cells from the bone marrow and sharpening their cytotoxic program. When the researchers combined clofoctol with an anti-PD-1 antibody, the treated animals showed greater intratumoral CD8-positive T cell abundance and effector activity, tighter tumor control, and significantly prolonged survival compared with either monotherapy.

The implications extend beyond glioblastoma itself. The finding that a systemically administered, clinically familiar small molecule can redistribute T cells from a bone marrow reservoir and enhance their killing capacity suggests a generalizable strategy for tumors characterized by T-cell sequestration and exhaustion. It also adds to a growing appreciation that the bone marrow acts as a dynamic immunological compartment in cancer, one that can be therapeutically targeted rather than simply observed. If the mechanisms hold up in further studies, clofoctol-like approaches could complement checkpoint blockade in other poorly immunotherapy-responsive cancers, where the limiting factor is not T-cell priming but T-cell delivery and function.

Considerable caution is nonetheless warranted before extrapolating to patients. The findings derive from a single murine model, and glioblastoma models have a well-documented history of promising immunotherapy results that failed to translate into human benefit. The authors themselves emphasize that the link between BCL9 and the observed signaling changes requires further investigation, and the dosing, safety, and pharmacokinetic questions specific to combining an antibiotic with checkpoint inhibitors in the setting of brain tumors remain open. Still, the study exemplifies the promise of drug repurposing viewed through an immunological lens: an old molecule, examined with modern flow cytometry, chemoproteomics, and combination-design thinking, reveals an unexpected capacity to reorganize the immune system in ways that make immunotherapy work better. For a disease whose median survival has barely moved in decades, that is a direction worth pursuing with urgency.

Subject of Research: Repurposing the antibiotic clofoctol to enhance T-cell-mediated immunotherapy response in glioblastoma

Article Title: Clofoctol promotes systemic T-cell redistribution and intratumoral cytotoxicity to improve the response to PD-1 blockade in glioblastoma

Article References: Clofoctol promotes systemic T-cell redistribution and intratumoral cytotoxicity to improve the response to PD-1 blockade in glioblastoma. (n.d.). https://doi.org/10.1007/s00262-026-04544-3

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04544-3

Keywords: glioblastoma, clofoctol, drug repurposing, immunotherapy, PD-1 blockade, CD8-positive T cells, bone marrow, tumor microenvironment, BCL9, granzyme B, immune checkpoint blockade, Cancer Immunology Immunotherapy

The motivation behind the work lies in the arithmetic of the resistance crisis. In 2021, an estimated 4.71 million deaths worldwide were associated with bacterial antimicrobial resistance, including 1.14 million deaths directly attributable to it. Conventional antibiotics typically disable a single bacterial target, which means a single mutation can confer resistance. Newer strategies therefore seek agents that attack bacteria through several mechanisms at once, making it far harder for pathogens to survive. Antimicrobial peptides, the cationic membrane-attack molecules of the innate immune system, embody this philosophy, but their clinical use has been hampered by susceptibility to proteolysis, poor pharmacokinetics, and toxicity. Peptidomimetics, small molecules that mimic the architecture of these peptides, promise to retain their killing power while shedding their liabilities.

Clofoctol offered an unusually attractive starting point. Unlike generic hydrophobic scaffolds, it came with a documented history in humans: established pharmacokinetic behavior, pulmonary concentrations well above the levels needed to inhibit bacteria, and known effects on bacterial energy metabolism, including lowered intracellular ATP and disrupted membrane permeability. Its weaknesses were equally clear. It was essentially inactive against Gram-negative bacteria, poorly soluble in water, and potentially cytotoxic. Its precise molecular target had never been identified. Previous attempts to revive the drug had focused on reformulation and combination therapy, such as loading it into PLGA nanoparticles for lung delivery or pairing it with colistin against resistant Gram-negative pathogens. No one had yet redesigned the molecule itself.

The chemistry team, led by Jiayong Liu and colleagues, focused modifications on the phenolic hydroxyl group of clofoctol’s biphenyl scaffold, which defines the molecule’s hydrophobic domain. Through a modular synthetic route, they installed a library of cationic substituents, diethylamine groups, guanidinium groups, and chains of the amino acid arginine, connected by spacers of varying length. Each analogue was tested against a panel of Gram-positive and Gram-negative strains, including MRSA, Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae, with minimum inhibitory concentrations measured by standardized broth microdilution and hemolysis assessed against rabbit red blood cells.

The structure–activity relationships that emerged were instructive. Simple alkyl appendages abolished activity entirely, confirming that positive charge is essential for electrostatic engagement with negatively charged bacterial membranes. Spacer length proved critical: a four-carbon linker balanced potency and selectivity, while longer or shorter chains degraded one or both. Among the cationic groups, arginine emerged as the star. Tri-arginine substitution with a C-terminal methyl ester produced compound 30, which inhibited Gram-positive bacteria at just 0.39 micrograms per milliliter, a fourfold improvement over clofoctol on a weight basis, and brought E. coli activity from greater than 50 micrograms per milliliter down to 1.56. Its hemolytic activity was undetectable even at 200 micrograms per milliliter, yielding a selectivity index exceeding 512.

Compound 30 also tackled some of the most feared hospital pathogens. It retained potency against carbapenem-resistant Enterobacterales strains of E. coli and Klebsiella at concentrations of 1.56 to 3.125 micrograms per milliliter, conditions under which amoxicillin was essentially inert. Quantitative analysis of the SAR data reinforced a key design principle: calculated lipophilicity correlated negatively with both potency and selectivity, meaning that simply making the molecule greasier did not help. Success required a calibrated balance of charge and hydrophobicity, precisely the balance that tri-arginine esterification achieved. The modification also cured clofoctol’s solubility problem; compound 30 remained clear in water at 100 milligrams per milliliter, a concentration at which the parent drug was visibly insoluble even at one-tenth that level.

Time-kill experiments revealed remarkably fast bactericidal kinetics. At eight times the MIC, compound 30 completely eradicated both S. aureus and E. coli cultures within one hour, whereas vancomycin needed far longer and amoxicillin required a full day. Serial passage experiments underscored another advantage: over 21 transfers, the compound’s MIC never shifted, while norfloxacin resistance in S. aureus rose 256-fold by day 11 and amoxicillin resistance in E. coli climbed 16-fold by day 16. The compound also throttled biofilms, reducing S. aureus biofilm formation by more than 93 percent at twice the MIC and dismantling 83 percent of established E. coli biofilms at four times the MIC. Activity remained stable under physiological salt concentrations, a hurdle that defeats many cationic antimicrobials.

Mechanistic probing pointed to membrane disruption as the best-supported component of the compound’s action. SYTOX Green uptake, NPN permeability assays, and Live/Dead staining all showed concentration-dependent compromise of bacterial membrane integrity, and compound 30 displaced a fluorescent probe from lipopolysaccharide, the anchor of the Gram-negative outer membrane, by more than 80 percent at twice the MIC. Additional effects layered on top of this primary mechanism. In a purified-enzyme assay, compound 30 inhibited E. coli topoisomerase IV-mediated DNA decatenation by 96 percent at twice the MIC, and molecular docking into the ATP-binding pocket of the ParE subunit yielded a plausible binding pose at −10.2 kilocalories per mole, although the authors caution that intracellular target engagement has not yet been demonstrated. Treatment also depleted intracellular ATP and triggered reactive oxygen species accumulation; adding the ROS scavenger N-acetylcysteine raised the compound’s MIC four- to eightfold, supporting a functional contribution of oxidative stress to bacterial killing.

Transcriptome sequencing of E. coli after two hours of exposure identified 129 differentially expressed genes among 4,491 analyzed, with enrichment in the tricarboxylic acid cycle, methionine biosynthesis, and fatty acid catabolism, a pattern consistent with the observed energy and redox disturbances. The authors are careful to frame these as treatment-associated cellular responses rather than proof of direct targets, and the hierarchy among membrane damage, metabolic collapse, oxidative stress, and topoisomerase inhibition remains to be causally disentangled. What is clear is that the compound engages bacteria on multiple fronts, which plausibly explains both its rapid killing and its stubborn refusal to select for resistance under laboratory conditions.

The in vivo results, though early-stage, provide the most compelling evidence yet that the strategy can translate. In a murine keratitis model, topical 0.5 percent compound 30 reduced corneal S. aureus burden by 4.65 log units, statistically indistinguishable from 5 percent vancomycin, and cut P. aeruginosa burden by 3.81 log units, comparable to 0.3 percent gatifloxacin. Ocular safety testing with fluorescein staining showed no corneal epithelial damage even at three times the therapeutic dose. The authors emphasize that considerable work remains before clinical development: pharmacokinetics, corneal penetration, metabolic stability, long-term repeat-dose safety, broader panels of clinical isolates, and the precise causal mechanisms all require further study. Still, the study demonstrates a principle with wide implications. Rather than designing peptide mimics from scratch or hunting for entirely new scaffolds, medicinal chemists can take clinically validated drugs, install the cationic amphiphilic features that make antimicrobial peptides lethal, and produce candidates that are soluble, selective, fast-acting, and resistance-resistant. As the pipeline of conventional antibiotics continues to run dry, that recipe may prove one of the most practical paths forward.

Subject of Research: Development of clofoctol-derived cationic amphiphilic peptidomimetics as multi-mechanism broad-spectrum antibacterial agents

Article Title: Clofoctol-derived amphiphilic peptidomimetics exhibit broadened antimicrobial activity via multiple contributing mechanisms

Article References: Liu, J., Lin, J.-H., Wang, W., Li, H., Zheng, Y., Zhang, Y., Chen, M., Zhong, R., Xing, C., Dang, Y., Chang, H., Liu, S., & Lin, S. (2026). Clofoctol-derived amphiphilic peptidomimetics exhibit broadened antimicrobial activity via multiple contributing mechanisms. Journal of Advanced Research. https://doi.org/10.1016/j.jare.2026.09.007

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.09.007

Keywords: antimicrobial resistance, clofoctol, peptidomimetics, antibiotics, membrane disruption, MRSA, Gram-negative bacteria, biofilms, keratitis, drug discovery, topoisomerase IV, reactive oxygen species